ASTRUM-007
Regimen
- Experimental
- serplulimab + cisplatin/5-FU (Q2W)
- Control
- placebo + cisplatin/5-FU (Q2W)
Population
Previously untreated locally advanced or metastatic ESCC with PD-L1 CPS >=1
Key finding
mPFS 5.8 vs 5.3 mo (HR 0.60, 95% CI 0.48-0.75, p<0.0001); mOS 15.3 vs 11.8 mo (HR 0.68, 95% CI 0.53-0.87, p=0.002)
Source: PMID 36732627